Ann Wiegand

2.3k citations

17 papers · 1.7k indexed · 1 hit paper · h-index 11

Co-authors: John M. Coffin John W. Mellors Mary F. Kearney Frank Maldarelli Sarah Palmer Martin King Wei Shao George J. Hanna
Topics: HIV Research and Treatment (17 papers)HIV/AIDS drug development and treatment (13 papers)HIV/AIDS Research and Interventions (11 papers)
Cited by: Virology Infectious Diseases Immunology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Investigation PLoS ONE
Partner nations: United States South Africa Sweden

In The Last Decade

Ann Wiegand

17 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

2008 514 citations Sarah Palmer, Frank Maldarelli et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Ann Wiegand

Since Specialization

Citations

This map shows the geographic impact of Ann Wiegand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Wiegand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Wiegand more than expected).

Fields of papers citing papers by Ann Wiegand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Wiegand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Wiegand. The network helps show where Ann Wiegand may publish in the future.

Co-authorship network of co-authors of Ann Wiegand

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Wiegand. A scholar is included among the top collaborators of Ann Wiegand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Wiegand. Ann Wiegand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNA 2024 ·Proceedings of the National Academy of Sciences ·Adam A. Capoferri,Ann Wiegand,Feiyu Hong,Jana L. Jacobs,Jonathan Spindler,Andrew Musick,Michael J. Bale,Wei Shao,Michele D. Sobolewski,Anthony R. Cillo,Brian T. Luke,Christine M. Fennessey,Robert J. Gorelick,Rebecca Hoh,Elias K. Halvas,Steven G. Deeks,John M. Coffin,John W. Mellors,Mary F. Kearney	3
2	Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in Children 2021 ·mBio ·Michael J. Bale,(unknown),(unknown),Xiaolin Wu,Jonathan Spindler,Elias K. Halvas,Joshua C. Cyktor,Ann Wiegand,Wei Shao,Mark F. Cotton,Stephen H. Hughes,John W. Mellors,John M. Coffin,Gert U. van Zyl,Mary F. Kearney	9
3	Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations 2021 ·mBio ·(unknown),Rachel Van Duyne,(unknown),Jennifer L. Groebner,Ann Wiegand,John W. Mellors,Mary F. Kearney,Eric O. Freed	28
4	HIV Infected T Cells Can Proliferate in vivo Without Inducing Expression of the Integrated Provirus 2019 ·Frontiers in Microbiology ·Andrew Musick,Jonathan Spindler,Eli Boritz,Liliana Pérez,(unknown),Sean C. Patro,Michele D. Sobolewski,Michael J. Bale,Carolyn Reid,Brandon F. Keele,Adam A. Capoferri,Wei Shao,Ann Wiegand,Francesco R. Simonetti,John W. Mellors,Stephen H. Hughes,John M. Coffin,Frank Maldarelli,Mary F. Kearney	44
5	A9 A method to obtain full-length HIV proviral sequences and their sites of integration 2019 ·Virus Evolution ·Sean C. Patro,Xiaolin Wu,Shuang Guo,Michael J. Bale,Ann Wiegand,Jonathan Spindler,Christine M. Fennessey,Elias K. Halvas,Brandon F. Keele,Stephen H. Hughes,John W. Mellors,John M. Coffin,Jason W. Rausch,Mary F. Kearney	1
6	Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults 2018 ·PLoS ONE ·Mary F. Kearney,Jonathan Spindler,Ann Wiegand,Wei Shao,Richard Haubrich,Sharon A. Riddler,Christina M. Lalama,Michael D. Hughes,John M. Coffin,John W. Mellors	2
7	No evidence of HIV replication in children on antiretroviral therapy 2017 ·Journal of Clinical Investigation ·Gert U. van Zyl,(unknown),Ann Wiegand,William R. McManus,Michael J. Bale,Elias K. Halvas,Brian T. Luke,Valerie F. Boltz,Jonathan Spindler,Barbara Laughton,Susan Engelbrecht,John M. Coffin,Mark F. Cotton,Wei Shao,John W. Mellors,Mary F. Kearney	55
8	Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir 2017 ·PLoS Pathogens ·John Bui,Michele D. Sobolewski,Brandon F. Keele,Jonathan Spindler,Andrew Musick,Ann Wiegand,Brian T. Luke,Wei Shao,Stephen H. Hughes,John M. Coffin,Mary F. Kearney,John W. Mellors	174
9	Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART 2017 ·Proceedings of the National Academy of Sciences ·Ann Wiegand,Jonathan Spindler,Feiyu Hong,Wei Shao,Joshua C. Cyktor,Anthony R. Cillo,Elias K. Halvas,John M. Coffin,John W. Mellors,Mary F. Kearney	124
10	No evidence for ongoing HIV replication in lymph nodes during suppressive ART 2017 ·Journal of Virus Eradication ·William R. McManus,Michael J. Bale,Jonathan Spindler,Ann Wiegand,Andrew Musick,Xiaolin Wu,(unknown),Stephen H. Hughes,Brandon F. Keele,Rebecca Hoh,(unknown),John M. Coffin,John W. Mellors,Steven G. Deeks,Mary F. Kearney	1
11	Ongoing HIV Replication During ART Reconsidered 2017 ·Open Forum Infectious Diseases ·Mary F. Kearney,Ann Wiegand,Wei Shao,William R. McManus,Michael J. Bale,Brian T. Luke,Frank Maldarelli,John W. Mellors,John M. Coffin	49
12	Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy 2015 ·Journal of Virology ·Mary F. Kearney,Ann Wiegand,Wei Shao,John M. Coffin,John W. Mellors,Michael M. Lederman,Rajesh T. Gandhi,Brandon F. Keele,Jonathan Z. Li	107
13	Baseline Natural Killer and T Cell Populations Correlation with Virologic Outcome after Regimen Simplification to Atazanavir/Ritonavir Alone (ACTG 5201) 2014 ·PLoS ONE ·John E. McKinnon,Robbie B. Mailliard,Susan Swindells,Timothy Wilkin,Luann Borowski,(unknown),Barbara Bastow,Mary F. Kearney,Ann Wiegand,John W. Mellors,Charles R. Rinaldo,(unknown)	1
14	Immediate antiviral therapy appears to restrict resting CD4 ⁺ cell HIV-1 infection without accelerating the decay of latent infection 2012 ·Proceedings of the National Academy of Sciences ·Nancie M. Archin,Naveen K. Vaidya,JoAnn D. Kuruc,Abigail Liberty,Ann Wiegand,Mary F. Kearney,Myron S. Cohen,John M. Coffin,Ronald J. Bosch,Cynthia L. Gay,Joseph J. Eron,David M. Margolis,Alan S. Perelson	169
15	Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy 2009 ·Proceedings of the National Academy of Sciences ·Jason B. Dinoso,(unknown),Ann Wiegand,Sarah Palmer,Stephen J. Gange,Lisa M. Cranmer,(unknown),(unknown),Adam M. Spivak,Timothy Brennan,Mary F. Kearney,Michael A. Proschan,JoAnn M. Mican,Catherine Rehm,John M. Coffin,John W. Mellors,Robert F. Siliciano,Frank Maldarelli	343
16	Regimen Simplification to Atazanavir‐Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48‐Week Clinical and Virologic Outcomes 2009 ·The Journal of Infectious Diseases ·Timothy Wilkin,John E. McKinnon,A. Gregory DiRienzo,Katie R. Mollan,Courtney V. Fletcher,David M. Margolis,Barbara Bastow,(unknown),William C. Woodward,Catherine Godfrey,Ann Wiegand,Frank Maldarelli,Sarah Palmer,John M. Coffin,John W. Mellors,Susan Swindells	44
17	Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapybreakdown → 2008 ·Proceedings of the National Academy of Sciences ·Sarah Palmer,Frank Maldarelli,Ann Wiegand,Barry Bernstein,George J. Hanna,Scott C. Brun,Dale J. Kempf,John W. Mellors,John M. Coffin,Martin King	514

About Ann Wiegand

Ann Wiegand is a scholar working on Virology, Infectious Diseases and Epidemiology, having authored 17 papers that have together received 1.7k indexed citations. Recurring topics across this work include HIV Research and Treatment (17 papers), HIV/AIDS drug development and treatment (13 papers) and HIV/AIDS Research and Interventions (11 papers). The work is most often cited by research in Virology (1.6k citations), Infectious Diseases (1.3k citations) and Immunology (402 citations). Ann Wiegand has collaborated with scholars based in United States, South Africa and Sweden. Frequent co-authors include John M. Coffin, John W. Mellors, Mary F. Kearney, Frank Maldarelli, Sarah Palmer, Martin King, Wei Shao, George J. Hanna, Scott C. Brun and Barry Bernstein. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact